Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence

Petzold, Axel; Braithwaite, Tasanee; Oosten, Bob W. van; Balk, Lisanne J.; Martínez-Lapiscina, Elena H.; Wheeler, Russell; Wiegerinck, Nils; Waters, Christiaan; Plant, Gordon T.

doi:10.1136/jnnp-2019-321653

Cited by 26 publications

(28 citation statements)

References 66 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also did not find an association between symptom duration and long-term visual function but cannot address whether hyperacute corticosteroid treatment before the onset of vision loss would have aborted the attack. 18 Second, the ONTT data are more than 25 years old. Although little evidence suggests that the diagnosis or natural history of optic neuritis has changed substantially over time, external validation in a more modern cohort is needed.…”

Section: Limitationsmentioning

confidence: 99%

Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Using corticosteroids to treat acute demyelinating optic neuritis has been identified as an area for shared decision-making. However, no analysis exists to support personalized shared decision-making that considers long-and short-term treatment benefits. OBJECTIVE To develop models of individual-level visual outcomes for patients with optic neuritis. DESIGN, SETTING, AND PARTICIPANTS This secondary analysis of the Optic Neuritis Treatment Trial (ONTT), a randomized clinical trial, was performed at 14 academic eye centers and 1 large community eye center. Adults aged 18 to 46 years with incident acute unilateral optic neuritis within 8 days of vision loss onset were included.

show abstract

Section: Limitationsmentioning

confidence: 99%

Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Optic neuritis is an important cause of potentially irreversible vision impairment [2]. The most typical cause is a demyelinating inflammatory lesion, which can be isolated or associated with multiple sclerosis.…”

Section: Physician Perspectivementioning

confidence: 99%

Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives

Braithwaite

Wiegerinck²,

Petzold

et al. 2020

Ophthalmol Ther

Self Cite

View full text Add to dashboard Cite

This article, co-authored by a patient affected by bilateral, recurrent, atypical optic neuritis, and clinicians, discusses the mental burden of living with uncertainty and the possibility of further sight loss, along with the side effects of treatment. The patient shares some of the challenges, coping strategies, and the value they found in creating and participating in a patient support group. The physicians consider whether current clinical measures adequately capture the outcomes that matter to patients and discuss the role for patient-reported outcome measures (PROMs). We identify technological advances that are lowering traditional barriers to the use of PROMs in research and routine clinical care and look towards new PROM instruments enhancing shared patient-physician care in the future.

show abstract

“…Two areas of treatment are under further investigation. The first is whether hyperacute, or very early, treatment, results in a better outcome, 107 and second the role of delayed treatment with PLEX.…”

Section: Myelin Oligodendrocyte Glycoprotein Igg Associated Disordermentioning

confidence: 99%

Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoproteinIgGassociated disorder: A comprehensive neuro‐ophthalmic review

Sharma

Bhatti

Danesh‐Meyer

2021

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Neuromyelitis optica spectrum disorder (NMOSD) is an antibody‐mediated inflammatory disease of the central nervous system that involves the optic nerves, spinal cord, and often other specific brain regions such as area postrema of the medulla. NMOSD was formerly classified as a variant of multiple sclerosis (MS), given the similar symptomatology and relapsing course but is now considered to have distinct clinical, paraclinical, immunological and prognostic features. The discovery of aquaporin 4 (AQP4) immunoglobulin G (IgG) has improved the ability to diagnose NMOSD. AQP4‐IgG targets the astrocytic AQP4 water channel leading to complement activation and increased blood‐brain barrier permeability. Accurate and early diagnosis is crucial as timely treatment may result in mitigation of long‐term disability. Myelin oligodendrocyte glycoprotein (MOG)‐IgG associated disorder (MOGAD) is a distinct nosologic entity, which has been more recently described. Its clinical spectrum partly overlaps that of seronegative NMOSD and MS. Although it is considered to have fewer relapses and better prognosis than NMOSD, the clinical course and outcome of MOGAD has not been fully characterized.

show abstract

Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence

Cited by 26 publications

References 66 publications

Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis

Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis

Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives

Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoproteinIgGassociated disorder: A comprehensive neuro‐ophthalmic review

Contact Info

Product

Resources

About